【摘要】 目的系统评价细胞色素P450酶2C19(CYP2C19)的基因多态性与他莫昔芬治疗乳腺癌患者疗效的关系。方法检索相关中英文数据库,根据文献纳入和排除标准,收集CYP2C19基因多态性与他莫昔芬治疗乳腺癌患者的相关文献。以无复发生存率(RFS)作为评价指标,用Cochrane协作网提供的RevMan5.3软件进行Meta分析。结果共纳入8篇文献,包含3261例对象。CYP2C19*2非突变体的RFS风险是突变体的1.13倍(OR=1.13,95%CI:0.92~1.40),但差异无统计学意义(P>0.05);CYP2C19*17非突变体的RFS风险是突变体的1.22倍(OR=1.22,95%CI:0.94~1.57),但差异无统计学意义(P>0.05)。结论 CYP2C19*2、*17基因多态性与服用他莫昔芬乳腺癌患者的疗效可能无相关性。更多还原

【Abstract】 Objective To assess the relationship between cytochrome P450 2 C19( CYP2 C19) polymorphisms and effect of the tamoxifen( TAM) in the treatment of beast cancer by performing a meta-analysis.Methods The relevant Data Base were systematically searched for clinical studies on the CYP2 C19 polymorphisms of TAM for breast cancer patients. The literatures were screened according to the inclusion and exclusion criteria. Then,the data were extracted and the methodologically quality of included studies were also examined,recurrence-free survival( RFS) as an evaluation indicator. Meta-analysis was carried out by using Rev Man 5. 3 software from Cochrane Network. Results A total of8 studies involving 3261 subjects were included. The results of meta-analysis showed that there was no significant difference in CYP2 C19 * 2 gene mutation for RFS of breast cancer patients using TAM( OR = 1. 13,95% CI: 0. 92-1. 40,P > 0. 05),as well as CYP2 C19 * 17( OR =1. 22,95% CI: 0. 94-1. 57,P > 0. 05). Conclusion The CYP2 C19 polymorphisms might be not associated with the effect of TAM on the breast cancer patients.更多还原